Skip to Content
Merck
All Photos(1)

Documents

1091200

USP

Captopril

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H15NO3S
CAS Number:
62571-86-2
Molecular Weight:
217.29
Beilstein:
477887
MDL number:
MFCD00168073
UNSPSC Code:
41116107
PubChem Substance ID:
329749226
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

captopril

manufacturer/tradename

USP

mp

104-108 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChI key

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Captopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Captopril and Hydrochlorothiazide Tablets
  • Captopril Compounded Oral Solution
  • Captopril Compounded Oral Suspension
  • Captopril Tablets

Biochem/physiol Actions

Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1091221

Captopril disulfide, United States Pharmacopeia (USP) Reference Standard

C0430000

Captopril, European Pharmacopoeia (EP) Reference Standard

Y0000435

Captopril impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001182

Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001221

Captopril impurity D, European Pharmacopoeia (EP) Reference Standard

Y0001219

Captopril impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001220

Captopril impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001450

Captopril impurity J, European Pharmacopoeia (EP) Reference Standard

BP538

Captopril, British Pharmacopoeia (BP) Reference Standard

BP500

Captopril disulfide, British Pharmacopoeia (BP) Reference Standard

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H341,H360F

Hazard Classifications

Muta. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Samir Attoub et al.
Annals of the New York Academy of Sciences, 1138, 65-72 (2008-10-08)
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease
R I Ogilvie et al.
The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)
Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)
Antonio C M Camargo et al.
Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)
The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the
A Schattner et al.
The American journal of the medical sciences, 322(4), 236-240 (2001-10-27)
Two elderly patients, treated with captopril for left ventricular dysfunction and diabetes, developed severe cholestatic jaundice for which no alternative explanation could be found. The jaundice resolved completely after discontinuation of the drug. A review of the literature identifies a
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service